Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS.
Yue YangDominic RoweHeather McCannClaire E ShepherdJillian June KrilMatthew C KiernanGlenda M HallidayRachel H TanPublished in: Neuropathology and applied neurobiology (2023)
These findings, in this first postmortem investigation of patients with ALS in CuATSM trials, demonstrate that in contrast to that seen in preclinical models of disease, CuATSM does not significantly alleviate neuronal pathology or astrogliosis in patients with ALS.